Therefore, these results could support that 1H-MRS is a noninvasive, valid and objective biomarker to evaluate the effects of MAO-B inhibitors on the decrease of neuronal degeneration in PD, and then on the slowing of disease progression. This evidence concerns the gene MAOB and Parkinson disease.